HR8431 is an early-stage bill that would expand the FDA's accredited third-party certification program for food safety audits. With zero funding authorization and no direct causal chain to any publicly traded company at this stage, it has no near-term market impact.
TICKER INTELLIGENCE
Conagra Brands, Inc. ($CAG)
NYSE/NASDAQ: CAG
Washington Intelligence
2
Active Bills
1
Gov't Contracts
50
Congressional Trades
$CAG is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 3 active Congressional signals mentioning $CAG, including 2 bills and 1 federal contract. The legislative sentiment is currently mixed, with both supportive and challenging policy signals in play.
Congressional Trades in $CAG
50 filings⚠ Rep. Cisneros bought $1K-$15K in CRWD on May 15, 2026 — 5 days before HR8880 (a bill boosting cybersecurity for small businesses) was introduced.
⚠ Gilbert Cisneros bought $100,001 - $250,000 in TSM on 2026-02-09, one day before S2722, the "Taiwan Energy Security and Anti-Embargo Act of 2026," advanced to the Senate Legislative Calendar, a bullish signal for the company.
⚠ Rep. Johnson bought $1K-$15K in MRK on Jan 17, 2025 — 35 days before HR1492 was introduced, a bill extending Medicare price-negotiation protections for small-molecule drugs like those from Merck.
Federal Contracts Awarded to $CAG
1 foundRelated Sectors
Congressional Legislation Affecting Conagra Brands, Inc. ($CAG)
The FSMA Fee Technical Corrections Act is a procedural bill that adjusts FDA reinspection and recall fees to a $15,000 inflation-adjusted base for large food manufacturers starting FY2026. The bill is early-stage (referred to committee) with no market-moving impact. Real market data shows no correlation with this bill—the sector's 30-day declines (GIS -5.83%, CAG -9.35%, CPB -7.45%, HSY -11.38%) reflect broader consumer staples weakness, not legislative action.
→ Event-driven cost increase for any facility that triggers FDA reinspection or a recall order. Fee is immaterial relative to Conagra's revenue ($12B+ annually).
Understanding These Signals
Get Full Access to Conagra Brands, Inc. ($CAG) Signals
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →